Securden, Inc., a leading provider of Privileged Access and Identity Security solutions, today announced that it has been recognized in the Gartner research report, "How to Manage Admin Privileges on ...

PE: How can teams reduce patient burden without weakening their science? Schwab: Number one is lean trial design. We should ...

A total of 91,403 sessions targeted public LLM endpoints to find leaks in organizations' use of AI and map an expanding ...

Security researchers with GreyNoise say they've detected a campaign in which the threat actors are targeting more than 70 popular AI LLM models in a likely reconnaissance mission that will feed into ...

As 2026 begins, a subtle shift is underway in the air-cargo map of the Americas. The Caribbean, long treated as peripheral or ...

Two coordinated campaigns generated more than 91,000 attack sessions against AI infrastructure between October and January, ...

Developers have a growing array of options for AI-powered low-code and no-code development tools. But using them to their ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for its novel, orally administered, highly selective, and ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...

Novo Nordisk A/S’s obesity pill will allow it to tap into a massive population of patients that have not yet taken GLP-1s, ...